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Endogenous Opioid Modulation of Pancreatic Hormone Secretion: 
Studies in Dogs 
Ellis R. Levin, Tadataka Yamada, Seymour Levin, and Steven Mills 
The role of endogenous opioid peptides in the modulation of secretion of hormones from the endocrine pancreas was 
studied in dogs. In response to insulin-induced hypoglycemia, plasma glucagon secretion significantly increased, followed 
by an increase in plasma somatostatin immunoreactivity. Pretreatment with the opiate antagonist, naloxone. prevented 
the somatostatin response but had no effect on the augmented glucagon secretion. Neither the degree of hypoglycemia nor 
recovery from the induced glucose nadir were affected by naloxone. Arginine Hcl administration resulted in prompt 
increases in immunoreactive glucagon and insulin secretion, as well as a rise in serum glucose. Pretreatment with naloxone 
failed to affect any of these responses. Our results suggest that endogenous opioid peptides mediate the somatostatin 
response following hypoglycemia-induced glucagon secretion 
o 1988 by Grune & Stratton, Inc. 
E NDOGENOUS opioid peptides have been local- ized in the islets of Langerhans in rats,‘.’ inspir- 
ing a number of studies of the effects of these peptides 
on hormone secretion from the endocrine pancreas. In 
vitro perfusion studies in dogs and rats3-5 have demon- 
strated that p-receptor active opiates fl-endorphin and 
morphine stimulate insulin and glucagon secretion 
while a-receptor active opioids met and leu-enkephalin 
inhibit insulin and glucagon release. Thus, opiates 
acting at different receptors may have opposite actions 
on the pancreas. Studies in vivo have shown that 
administration of pharmacologic doses of /3-endorphin 
increase plasma glucagon, insulin, and glucose in 
humans.6*7 Similar effects occur after the administra- 
tion of exorphins, dietary proteins with opiate-like 
activity.* Whether endogenous opioid peptides modu- 
late the endocrine pancreas response to secretagogues, 
including physiologic stimuli, has not been extensively 
studied. We, therefore, examined the secretion of 
glucagon and somatostatin immunoreactivity (SI) and 
the recovery of blood glucose after insulin-induced 
hypoglycemia while antagonizing endogenous opioid 
action. Further, we characterized the insulin, gluca- 
gon. glucose, and SI responses to arginine injection and 
determined whether endogenous opioid peptides mod- 
ify the hormonal response to this pancreatic secreta- 
gogue in dogs. 
MATERIALS AND METHODS 
Seven mongrel dogs, six male and one nonpregnant female, 18-25 
kg, were adapted to light harness restraint. The dogs were main- 
tained on Wayne Pro-Mix (Gardena, Calif). After an overnight fast. 
each dog underwent four separate sessions, studies beginning at 
approximately 0800 h each day, one to four days apart. Indwelling 
butterfly needles were inserted into a hind leg vein, kept patent with 
heparinized saline for drug administration and blood drawing. A 
45minute equilibration period postneedle insertion preceded all 
experiments. In the first experiment, 10 mL of blood was withdrawn 
at - 15 and - 1 minute for determination of serum glucose and 
insulin, plasma glucagon, and somatostatin immunoreactivity. At 
time 0. arginine Hcl 12.5 mmol was administered as an IV bolus over 
2 minutes and blood was withdrawn at 4. 7, 10. 15, and 30 minutes 
after arginine for hormone measurement. This protocol was similar 
to previous studies of arginine stimulation of the pancreas.’ After 
each blood sampling, an equal volume of saline was injected. Blood 
for glucagon was collected in ice-cold syringes, rapidly injected into 
test tubes containing benzamidine, and EDTA and cold centrifuged 
within 30 minutes, plasma frozen at -70 “C for subsequent assay. 
Blood for somatostatin was injected into tubes containing trasylol 
(2000 units/2 mL) and EDTA and processed similarly to glucagon. 
During the second session, blood was withdrawn at -46 minutes 
at which time naloxone 190 nmol/kg was given as an IV bolus. Blood 
for hormone measurements was then withdrawn at - 15 and - I 
minutes; arginine 12.5 mmol and naloxone 190 nmol/kg again was 
given at time 0 and blood withdrawn at times identical to the 
arginine alone experiment. 
The third session examined the effects of insulin-induced hypogly- 
cemia on blood glucose, plasma glucagon, and SI. Baseline hormone 
measurements were made at - 15 and - 1 minutes; at time 0, pork 
regular insulin 0.1 units/kg was administered and blood sampled at 
+ 15. +30, +45, +60, +75, and +90 minutes. During the fourth 
session, blood was withdrawn at -46 minutes and naloxone was 
given IV. Blood was then sampled at ~ 30, - 15, and - I minutes. At 
time 0, insulin 0.1 units/kg and naloxone 190 nmol/kg were 
administered and blood sampled identically to the insulin alone 
protocol. Serum glucose was determined by glucose oxidase method 
with a Beckman glucose analyzer. Immunoreactive insulin”’ and 
glucagon” were determined by radioimmunoassay. glucagon mea- 
surements utilizing 30K antiserum (Unger). Plasma somatostatin- 
like immunoreactivity was determined as previously described.“.” 
The raised antibody to somatostatin is directed against the central 
portion of the molecule (positions 4413). All response data were 
compared by analysis of variance and student’s t-test. P < 0.05 was 
considered significant. 
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Fig 1. Plasma immunoreective glucagon response to arginine 
12.5 mmol or arginine end neloxone 190 nmol/kg in dogs. Each 
point is the mean + SEM (n = 7). 
RESULTS 
Arginine Studies 
Arginine administration resulted in a marked 
increase in plasma glucagon immunoreactivity (mean 
basal IRG 73.7 * 8.4 [SE] pg/mL, mean peak IRG at 
4 min after arginine 112 * 20.6 [SE] pg/mL, P < 
0.05; Fig 1). Naloxone pretreatment had essentially no 
effect on basal glucagon secretion and failed to signifi- 
cantly affect the peak or total glucagon response to 
arginine (mean prenaloxone baseline IRG 74.3 + 13.4 
[SE] pg/mL, mean postnaloxone, prearginine baseline 
IRG 71.7 f 8.9 [SE] pg/mL, mean peak IRG at +4 
min 110 * 18.4 [SE] pg/mL). The variation in peak 
glucagon response seen with arginine and arginine plus 
naloxone was mainly due to the marked stimulation of 
glucagon secretion in one dog. Although the stimula- 
tory effect by arginine on glucagon was greater in the 
presence of naloxone at several time points, there was 
no statistically significant difference compared to 
arginine alone. Plasma insulin secretion was enhanced 
by arginine administration. Peak levels of insulin were 
noted 4 minutes after arginine and were significantly 
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Fig 2. Serum immunoreactive insulin responses to erginine 
12.5 mmol or arginine end neloxons 190 nmol/kg in dogs. Each 
point represents the mean _t SEM (n = 7). 
[SE] p/mL, mean peak IRI 27 -+ 4.1 p/mL, P < 0.01; 
Fig 2). Naloxone administered at -45 minutes 
resulted in a steady though nonstatistically significant 
rise in plasma insulin over the subsequent 45 minutes. 
Due to the higher baseline insulin level after the initial 
naloxone injection, arginine-stimulated insulin se- 
cretion was somewhat attenuated. Nevertheless, the 
total IRI secretion was still highly significant (P < 
0.05) and the peak IRI response at +4 minutes was 
comparable to that seen during the arginine alone 
experiment. Serum glucose rose significantly following 
arginine administration (Table 1). The peak glucose 
response occurred 4 minutes after arginine (mean 
basal glucose 102 * 4.6 mg/dL, mean basal glucose 
115 * 5.4 mg/dL, P < 0.05) and was not influenced by 
naloxone (mean prenaloxone baseline glucose 109 * 
5.6 mg/dL, mean peak glucose 122 + 10.2 mg/dL). 
Although the mean serum glucose levels after arginine 
plus naloxone were somewhat higher for 15 minutes 
compared to arginine alone, there was no significant 
difference between these two experiments. Plasma 
somatostatin immunoreactivity was moderately but 
statistically insignificantly stimulated by arginine. 
Pretreatment with naloxone had little effect on the SI 
response to arginine (data not shown). 
Table 1. Serum Glucose in Response to Arginine 12.5 mmol or Arginine and Naloxone 190 nmol/kg in Dogs 
Time kntn) 
-46 -15 -1 4 7 10 15 30 
Arginine - 106 k 3.3 102 & 4.6 115 % 5.4* 109 * 3.5 104 k 2.7 104 + 3.4 106 + 5 
Arginine and Naloxone 103 * 5.5 111 + 8.8 109 + 5.6 122 k 10.21 119 * 7.9’ 111 * 5.4 109 + 5.5 103 t 4.7 
l P < 0.05 compared to baseline by ANOVA and student’s t-test. Each point represent mean + SEM (n = 7) in mg/dL. 
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Table 2. Serum Glucose in Response to Insulin 0.1 p/kg or Insulin and Naloxone 190 nmol/kg in Dogs 
Time hnin) 
-46 -30 -15 -1 15 30 45 60 75 90 
Insulin - 103 -t 4.8 106 * 5.1 50.3 + 4.8” 56 +_ 3.5’ 66 + 6.3’ 80 -f 8.6 88 f 9.1 99 k 10.1 
Insulin and Naloxone 102 + 3 105 + 4.1 106 -+ 3.9 53 * 4.4’ 61 +_ 2.8’ 61 + 4.5 72 + 7.1 84 + 6.2 91.1 + 5.9 
l F < 0.05 compared to baseline by ANOVA and student’s t-test. Each point represents mean + SEM (n = 7) in mg/dL. 
Insulin-Induced Hypoglycemia Studies 
Insulin administration resulted in a marked fall of 
serum glucose (Table 2). Each dog demonstrated a 
marked biologic effect of insulin, with extreme 
lethargy occurring in all. The glucose nadir occurred 
15 minutes after insulin bolus (mean basal glucose 
106 t 5 [SE] mg/dL, mean nadir 50.3 * 4.8 [SE] 
mg/dL, P < 0.01) and recovery to near basal levels 
occurred by 90 minutes. Pretreatment with naloxone 
failed to affect the degree of insulin-induced hypogly- 
cemia and the glucose recovery course was similar to 
that following insulin alone. Insulin induced hypogly- 
cemia caused a significant (P < 0.05) stimulation of 
glucagon (mean basal IRG 78.9 rt 8.4 [SE] pg/mL, 
mean peak IRG 122 + 12 [SE] pg/mL) which was 
seen 15 minutes after the glucose nadir (Fig 3). 
Naloxone had no effect on basal glucagon levels; 
similarly, naloxone failed to influence hypoglycemia- 
induced glucagon secretion (mean basal IRG 73.9 t 
9.9 [SE] pg/mL, mean basal IRG 128 2 19 [SE] 
pg/mL, P < 0.05). Plasma somatostatin immunoreac- 
tivity rose significantly after insulin administration, 
the peak stimulation occurring at 30 minutes postinsu- 
150 - 
140 - D-_zz Insulin 








n 100 - 
90 - 
60’1 , I I I I I I I 1 
-46 -30 -15 0 15 30 45 60 75 90 
Time (minutes) 
Fig 3. Plasma glucagon immunoreactivity response to insulin 
0.1 u/kg or insulin and naloxone 190 nmol/kg in dogs. Each point is 
the mean + SEM (n = 7). 
lin (Fig 4) (basal mean of -30 and - 1 time points 
28.4 + 3 [SE] fmol/mL, mean peak at +30 min 39.1 
* 4.2 [SE] fmol/mL, P < 0.025). Pretreatment with 
naloxone caused a modest decrease in plasma SI and 
blunted the rise in plasma SI after insulin administra- 
tion 
DISCUSSION 
Many in vitro studies have suggested a role for 
endogenous opioid peptides in the regulation of hor- 
mone secretion from the endocrine pancreas.3-5*‘4*‘5 
Additionally, several in vivo human studies have dem- 
onstrated that administration of P-endorphin in phar- 
macologic doses6,’ increases plasma levels of insulin 
and glucagon, affecting glucose homeostasis. Few 
studies have addressed whether well-characterized 
stimuli to hormone secretion from the endocrine pan- 
creas in vivo act through endogenous opiates. Most 
important is the response to hypoglycemia. For our 
experiments, we selected a dose(s) of naloxone that 
would be expected to antagonize the systemic effects of 
endogenously secreted opiates. This is important 
because the site of secretion of endogenous opioid 
peptides may originate within the brain, ultimately 
affecting the endocrine pancreas.‘6-‘8 
Arginine He1 resulted in rapid increases of serum 
‘51/m 
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Fig 4. Plasma immunoreactive somatostatin responses to 
insulin 0.1 u/kg or insulin and naloxone 190 nmollkg in dogs. Each 
point represents the mean + SEM In = 6). l P c 0.025 compared to 
baseline (mean of -30 and - 1 time points): P c 0.05 compared to 
insulin and naloxone at identical time points. 
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glucose, insulin, and glucagon that were not affected 
by prior treatment with naloxone. Stimulation of the 
pancreas by this amino acid appears, then, not to be 
dependent on an opioid thus confirming the results of 
Morley et alI9 who reported similar findngs in 
humans. 
In contrast, we found that endogenous opioid pep- 
tides may play a role in the hormone response to 
hypoglycemia. Following insulin-induced glucopenia, 
glucagon and somatostatin secretion increased and 
recovery to normoglycemia ensued. The glucagon 
response in our dogs was unaffected by pretreatment 
with the opiate antagonist. However, the increased 
somatostatin secretion following hypoglycemia was 
prevented by naloxone administration. Insulin-induced 
hypoglycemia has been shown previously to result in 
the secretion of somatostatin immunoreactivity in 
humans.” Recently, it has been demonstrated that in 
dogs administration of P-casomorphin results in 
increased plasma somatostatin,21 and exorphin- 
induced somatostatin secretion can be inhibited by 
naloxone.22 In vitro studies of the isolated perfused dog 
pancreas, however, have shown that administered 
enkephalin decreases pancreatic SI secretion23; this 
may reflect activation of a different (A) opiate receptor. 
It is also conceivable that our measurements of 
somatostatin reflect a significant contribution from the 
gastrointestinal tract.24 Our findings suggest that in 
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response to hypoglycemia, pancreatic delta cell 
secretion is dependent upon endogenous opiates. Our 
results are particularly interesting in view of evidence 
for colocalization of /?-endorphin and somatostatin in 
the pancreatic D cell.2 
Induction of hypoglycemia or recovery from the 
induced glucose nadir was unaffected by naloxone. 
Since opiates have been shown to directly mediate 
hepatic glucose production2’ as well as insulin action,26 
glucose homeostasis could have been maintained 
despite effects on SI secretion. Bright et al*’ have 
shown that naloxone decreased recovery from hypogly- 
cemia in humans without altering glucagon secretion. 
The dissimilarity of our findings and those of Bright et 
al may reflect different effects of opiates in different 
species.*‘**’ 
In summary, the (Y- and &cell responses to arginine 
and the a-cell response to hypoglycemia are not modu- 
lated by endogenous opiates. Somatostatin secretion 
following hypoglycemia-induced glucagon secretion is 
dependent upon endogenous opioid peptides. Opiates 
can modulate glucose metabolism independent of their 
effects on the endocrine pancreas. Thus, integrated 
studies of the hepatic, pancreatic, and gastrointestinal 
tract responses to physiologic stimuli will be necessary 
to elucidate the role(s) of endogenous opiates in main- 
taining glucose homeostasis. 
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